Nan Fung-backed hearing aid producer Eargo's shares opened at double its IPO price after it floated above its range.

The Tencent-backed retail chain floated well above its range in New York and its shares have risen some 40% post-IPO.

Novo-backed congenital adrenal hyperplasia drug developer Spruce Biosciences has added approximately $14m to close its initial public offering.

The Alexandria Real Estate Equities-backed oncology therapy developer is floating in the middle of its range to raise $82.5m in its initial public offering.

GV-backed cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Novo remains the largest shareholder in the endocrine disorder drug developer, which went public in an upsized offering.

Big Hit Entertainment, the Netmarble-backed talent management agency and record company, priced its initial public offering at the top of its range.

The Roche, Novartis and Kraft Group-backed cancer therapy developer raised $182m in an upsized IPO where it floated above its range.

Sompo, Fujitsu and Relx-backed Palantir went public yesterday and fetched a $20.6bn valuation – only marginally above the $20.3bn it was worth in 2015.

Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.